NBIX - NEUROCRINE BIOSCIENCES INC
128.13
-1.510 -1.178%
Share volume: 903,600
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.19%
PREVIOUS CLOSE
CHG
CHG%
$129.64
-1.51
-0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-01-2024 | 08-01-2024 | 10-30-2024 | 02-10-2025 | 05-05-2025 | 07-30-2025 | 10-28-2025 | 02-11-2026 | |
| Assets | |||||||||
| Total Assets | 3.472 B | 3.305 B | 3.535 B | 3.719 B | 3.688 B | 3.890 B | 4.266 B | 4.632 B | |
| Current Assets | 1.799 B | 1.670 B | 1.877 B | 1.725 B | 1.638 B | 1.749 B | 2.158 B | 2.523 B | |
| Inventories | 37.200 M | 42.500 M | 45.800 M | 57.400 M | 59.100 M | 56.900 M | 69.300 M | 69.000 M | |
| Other Current Assets | 100.500 M | 120.200 M | 121.700 M | 112.100 M | 119.300 M | 120.700 M | 68.200 M | 115.800 M | |
| Short Term Investments | 814.300 M | 899.200 M | 878.900 M | 843.100 M | 749.400 M | 711.600 M | 774.600 M | 767.400 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 396.300 M | 139.700 M | 349.100 M | 233.000 M | 194.100 M | 264.000 M | 340.200 M | 713.000 M | |
| Total Non-current Assets | 863.900 M | 637.800 M | 770.600 M | 864.300 M | 909.500 M | 873.800 M | 1.117 B | 1.184 B | |
| Property Plant Equipment | 75.300 M | 80.100 M | 80.000 M | 82.600 M | 87.000 M | 91.700 M | 97.300 M | 89.800 M | |
| Other Assets | 1.598 B | 1.555 B | 1.578 B | 1.911 B | 1.963 B | 2.049 B | 2.010 B | 2.019 B | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 3.472 B | 3.305 B | 3.535 B | 3.719 B | 3.688 B | 3.890 B | 4.266 B | 4.632 B | |
| Total liabilities | 1.086 B | 795.800 M | 816.100 M | 1.129 B | 1.152 B | 1.196 B | 1.262 B | 1.378 B | |
| Total current liabilities | 712.900 M | 398.500 M | 429.700 M | 507.700 M | 522.900 M | 546.300 M | 638.000 M | 743.400 M | |
| Accounts Payable | 417.200 M | 358.500 M | 392.700 M | 461.600 M | 475.200 M | 489.500 M | 584.300 M | 674.300 M | |
| Other liabilities | 373.400 M | 397.300 M | 386.400 M | 621.300 M | 629.100 M | 649.200 M | 624.100 M | 635.000 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 373.400 M | 397.300 M | 386.400 M | 621.300 M | 629.100 M | 649.200 M | 624.100 M | 635.000 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 2.386 B | 2.509 B | 2.719 B | 2.590 B | 2.536 B | 2.694 B | 3.004 B | 3.253 B | |
| Common stock | 2.497 B | 2.555 B | 2.623 B | 2.555 B | 2.532 B | 2.597 B | 2.696 B | 2.792 B | |
| Retained earnings | -113.700 M | -48.700 M | 81.100 M | 29.200 M | -5.300 M | 84.500 M | 294.000 M | 447.700 M |